Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Japan, U.S. Discuss $19 Billion GlobalFoundries Chip Plant 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
Trump Bans CNN, MS NOW and Politico From White House 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
White House Bars CNN, MS NOW and Politico Reporters 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
SpaceX Nasdaq 100 Weight to More Than Double in Rebalance 
OpenAI Urges US-Led Global Standards for Frontier AI 
fnny Beta Launches With a Simple Idea: Find an Event, Show Up, Get Rewarded 
Add as a preferred source on Google
British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug developer Nuvalent Inc. (NASDAQ: NUVL) in a deal that could be worth more than $9 billion, according to a report published by the Financial Times on Tuesday.
Sources familiar with the matter said both companies are working toward finalizing an agreement as early as this week. However, discussions remain ongoing, and there is still a possibility that the deal could fall through if last-minute challenges arise.
If completed, the proposed acquisition would value Massachusetts-headquartered Nuvalent between $9 billion and $10 billion. The valuation represents a substantial premium over Nuvalent’s market capitalization, which stood at nearly $7 billion at the close of trading on Monday.
The potential takeover would mark GSK’s largest acquisition in more than a decade and rank among the most significant transactions in the company’s history. The move aligns with CEO Luke Miels’ strategy to expand and strengthen GSK’s oncology portfolio as the pharmaceutical industry increasingly focuses on innovative cancer treatments.
Nuvalent has gained attention for its work in developing targeted cancer therapies designed to address resistance mechanisms in tumors. Its lead drug candidate, neladalkib, is being developed for the treatment of lung cancer and is currently under review by U.S. regulators. Approval of the therapy could significantly enhance Nuvalent’s value and commercial prospects.
The reported deal comes during a period of heightened activity in the global biotechnology sector. According to Dealogic data cited in the report, biotech and pharmaceutical mergers and acquisitions have reached nearly $211 billion in announced transactions so far this year, highlighting strong demand for promising drug-development companies.
Should the acquisition move forward, it would further reinforce GSK’s commitment to cancer research and provide the company with valuable assets in the rapidly growing oncology market.
